3C-AL
Chemical compound
From Wikipedia, the free encyclopedia
3C-AL, also known as 4-allyloxy-3,5-dimethoxyamphetamine or as α-methylallylescaline (3C-allylescaline), is a psychedelic drug of the phenethylamine, amphetamine, and 3C families related to 3,4,5-trimethoxyamphetamine (TMA).[3][1][2] It is the amphetamine (3C) analogue of allylescaline.[3][1][2]
| |
| Clinical data | |
|---|---|
| Other names | 4-Allyloxy-3,5-dimethoxyamphetamine; 3,5-Dimethoxy-4-allyloxyamphetamine; α-Methylallylescaline; 3C-Allylescaline |
| Routes of administration | Oral[1][2] |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| Pharmacokinetic data | |
| Duration of action | 8–12 hours[1][2] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H21NO3 |
| Molar mass | 251.326 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 180 to 181 °C (356 to 358 °F) |
| |
| |
The drug has a dose range of 15 to 30 mg orally and a duration of 8 to 12 hours.[1][2] Its effects have been described as more visual than those of allylescaline.[1]
The drug is a potent partial agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors and targets.[2]
The chemical synthesis of 3C-AL has been described.[3][4]
3C-AL was described by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved), but he did not synthesize or test 3C-AL.[3] Instead, Daniel Trachsel synthesized 3C-AL in 2002[4] and described its properties and effects in 2013.[1] The pharmacology of 3C-AL was studied in greater detail in 2021.[2] It is a controlled substance in Canada under amphetamine blanket-ban language.[5]